NASDAQ:VRNA Verona Pharma (VRNA) Stock Price, News & Analysis $22.73 +0.58 (+2.62%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$22.01▼$23.0050-Day Range$11.48▼$22.9552-Week Range$11.39▼$23.72Volume617,862 shsAverage Volume860,063 shsMarket Capitalization$1.84 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Verona Pharma alerts: Email Address Verona Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.4% Upside$36.00 Price TargetShort InterestBearish11.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 6 Articles This WeekInsider TradingSelling Shares$71,046 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.58) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.24 out of 5 starsMedical Sector583rd out of 936 stocksPharmaceutical Preparations Industry267th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerona Pharma has only been the subject of 3 research reports in the past 90 days.Read more about Verona Pharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.92% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Verona Pharma has recently increased by 11.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRNA. Previous Next 3.0 News and Social Media Coverage News SentimentVerona Pharma has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Verona Pharma this week, compared to 2 articles on an average week.Search Interest26 people have searched for VRNA on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.MarketBeat Follows11 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,046.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verona Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verona Pharma are expected to grow in the coming year, from ($1.58) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -29.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -29.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 7.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verona Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Verona Pharma Stock (NASDAQ:VRNA)Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More VRNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRNA Stock News HeadlinesJuly 25 at 11:42 AM | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Slightly in Thursday TradingJuly 25 at 2:00 AM | globenewswire.comVerona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 23 at 6:12 AM | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Given New $37.00 Price Target at Canaccord Genuity GroupJuly 19, 2024 | uk.finance.yahoo.comVerona Pharma PLC (I9SA.DU)July 17, 2024 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Stock Price Up 4.8%June 30, 2024 | seekingalpha.comVerona Pharma Is Launching Ohtuvayre, Although There Will Be CompetitionJune 27, 2024 | reuters.comVerona Pharma's inhaled COPD therapy to be priced at $2,950 per monthJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 26, 2024 | reuters.comUS FDA approves Verona Pharma's therapy for 'smoker's lungs'June 26, 2024 | reuters.comUS FDA approves Verona Pharma's therapy for 'smoker's lungs'June 26, 2024 | globenewswire.comVerona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)June 20, 2024 | seekingalpha.comVerona Pharma: Next Week's PDUFA Date Ought To Provide An Upside CatalystJune 13, 2024 | investors.comWhy It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona StocksMay 23, 2024 | seekingalpha.comVerona Pharma: Key Inflection Point Directly AheadMay 13, 2024 | markets.businessinsider.comStrategic Financing Secures Verona Pharma’s Future Beyond 2026, Ensuring Buy RatingMay 10, 2024 | finance.yahoo.comVerona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic OverviewMay 10, 2024 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call TranscriptSee More Headlines Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRNA CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$38.00 Low Stock Price Target$33.00 Potential Upside/Downside+58.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.09% Return on Assets-21.24% Debt Debt-to-Equity Ratio0.22 Current Ratio18.40 Quick Ratio18.40 Sales & Book Value Annual Sales$460,000.00 Price / Sales3,993.56 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book7.33Miscellaneous Outstanding Shares80,820,000Free Float76,937,000Market Cap$1.84 billion OptionableOptionable Beta0.44 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. David S. Zaccardelli Pharm.D. (Age 60)President, CEO & Executive Director Comp: $1.27MMr. Mark W. Hahn (Age 61)Chief Financial Officer Comp: $858.29kDr. Kathleen A. Rickard M.D. (Age 66)Chief Medical Officer Comp: $650.83kMr. Andrew Fisher (Age 54)General Counsel Ms. Victoria StewartDirector of CommunicationsMr. Matthew CasbonVP of Sales, Marketing & TrainingMs. Ostra JewellSenior Vice President of Human ResourcesDr. Tara Rheault M.P.H. (Age 48)Ph.D., Chief Development Officer Mr. Christopher MartinChief Commercial OfficerMs. Caroline DiazSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsSummit TherapeuticsNASDAQ:SMMTElanco Animal HealthNYSE:ELANKrystal BiotechNASDAQ:KRYSOrganon & Co.NYSE:OGNApellis PharmaceuticalsNASDAQ:APLSView All CompetitorsInsiders & InstitutionsLegato Capital Management LLCBought 10,670 shares on 7/26/2024Ownership: 0.013%AMI Asset Management CorpBought 70,000 shares on 7/25/2024Ownership: 0.087%Hennion & Walsh Asset Management Inc.Bought 68,264 shares on 7/20/2024Ownership: 0.171%CWM LLCBought 2,000 shares on 7/10/2024Ownership: 0.003%Virtu Financial LLCBought 23,180 shares on 5/20/2024Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions VRNA Stock Analysis - Frequently Asked Questions How have VRNA shares performed this year? Verona Pharma's stock was trading at $19.88 on January 1st, 2024. Since then, VRNA stock has increased by 14.3% and is now trading at $22.73. View the best growth stocks for 2024 here. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.08. When did Verona Pharma IPO? Verona Pharma (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma's major shareholders? Top institutional shareholders of Verona Pharma include Hennion & Walsh Asset Management Inc. (0.17%), AMI Asset Management Corp (0.09%), Legato Capital Management LLC (0.01%) and CWM LLC. Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth, Martin Edwards and Lisa Deschamps. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR) and Inovio Pharmaceuticals (INO). This page (NASDAQ:VRNA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
